Life Biosciences moves Sinclair's epigenetic reprogramming drug ER-100 into Phase 1 trial
Olivier__OG · x · 2026-09-04
- The post relays Dr. David Sinclair's framing of aging as partly lost biological information — like a scratched CD where the music is intact but unreadable.
- Epigenetic restoration aims not to slow decline but to reset cells toward a younger, more functional state.
- Life Biosciences, co-founded by Sinclair, has moved ER-100 into a Phase 1 trial for optic nerve diseases including glaucoma and NAION. Early stage, safety first.
- AI is increasingly part of the discovery engine: genome mining, sequencing, proteomics, high-throughput screening, and pattern detection across large biological datasets.
- The bigger question: can some biological functions eventually be reset rather than just treated after damage.
More from Research
- HKU team launches The Imitator Game: a 4-level benchmark for intent-level robot imitation — YiMaTweets · 2026-09-04
- New paper: LLM outputs are far less diverse than their training data, and temperature tuning won't fix it — rohanpaul_ai · 2026-09-04
- Preprint Claiming Proof of Longstanding Unsolved Problem Faces Scrutiny Over Spelling Errors — Aizkmusic · 2026-09-04
- Ken Thompson's 'Trusting Trust' is a chillingly relevant warning for AI training — amasad · 2026-09-04
- AFAC2026 Finals: 20K-Contestant Financial AI Contest Opens Million-Sample Dataset — 量子位 · 2026-09-04
- POSTECH's PACE uses coordinated agents to surface hidden conflicts in user requests — POSTECH · 2026-09-04